Vantage logo

Esker joins the Tyk2 race

The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.

Vantage logo

Go or no go? The FDA plays hardball

April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.